The Elecsys pTau181 test is the second blood test cleared by the FDA this year for use in Alzheimer’s evaluation. In May, the ...

New research by UCLA Health has found a simple blood test could provide faster and more accurate diagnosis of ALS by ...

The US Food and Drug Administration (FDA) has granted clearance for Roche's Elecsys pTau181 test, a blood-based biomarker ...

Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s ...

Imagine this: someone you love has just heard the words “you have cancer.” They are meeting with their oncologist – perhaps even me, or one of my colleagues – and come to understand that there is ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

BeiGene is back with a new partnership and oncology campaign to raise awareness about biomarker testing for patients with chronic lymphocytic leukemia (CLL), a blood cancer marked by the ...

William J. Gradishar, MD, analyzes current guidelines for identifying targetable mutations in breast cancer, explores strategies to enhance biomarker testing for mutations like PIK3CA or AKT1, and ...

Please provide your email address to receive an email when new articles are posted on . Biomarker testing appeared inconsistent, with rates not reflecting guidelines. Less than 25% of oncologists ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Across all cancer types, less than 50% of patients underwent biomarker testing before first-line treatment. Many patients with advanced cancer do not receive guideline-recommended biomarker testing ...

The US Food and Drug Administration has given clearance to another blood test to help assess Alzheimer’s disease and other ...